C. Ravaglia (Forlì, Italy), Y. Kondoh (Seto (Aichi), Japan)
Characteristics and clinical management of IPF patients in Spain: prospective, observational, multicentric study (OASIS study).
A. Romero Ortiz (Granada, Spain), M. Rodríguez-Nieto (Madrid, Spain), A. Villar (Barcelona, Spain), E. Cano-Jiménez (Lugo, Spain), A. Ramón (Barcelona, Spain), S. Armengol (Barcelona, Spain), E. Alhaja (Barcelona, Spain), M. Artés (Barcelona, Spain)
|   |
Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis
D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), J. Gao (Stockholm, Sweden), C. Li (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), C. Sköld (Stockholm, Sweden)
| |
Acute Exacerbation of IPF - Experience of a Portuguese RICU
J. Rodrigues Barbosa (Lisboa, Portugal), S. Salgado (Lisboa, Portugal), P. Esteves (Lisboa, Portugal), C. Bárbara (Lisboa, Portugal)
| |
Russian IPF Registry: time of inclusion impacts patients’ status
S. Chikina (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), I. Tyurin (Moscow, Russian Federation), A. Cherniak (Moscow, Russian Federation), Z. Merzhoeva (Moscow, Russian Federation)
| |
Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry
J. Gao (Stockholm, Sweden), D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), C. Li (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), M. Sköld (Stockholm, Sweden)
| |
Prevalence of idiopathic pulmonary fibrosis in Japan and the US: a claims-based retrospective study
Y. Kondoh (Aichi, Japan), T. Suda (Shizuoka, Japan), Y. Hongo (Tokyo, Japan), M. Yoshida (Tokyo, Japan), S. Hiroi (Tokyo, Japan), K. Iwasaki (Tokyo, Japan), T. Takeshima (Tokyo, Japan), S. Homma (Tokyo, Japan)
| |
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
S. Nayci (Mersin, Turkey), D. Polat (Mersin, Turkey), E. Ozgur (Mersin, Turkey), C. Özge (Mersin, Turkey)
| |
Factors influencing best tolerated dose of pirfenidone (PFD) in patients with IPF
N. Agrawal (Mumbai, India), P. Vaidya (Mumbai, India), R. Shah (Mumbai, India), V. Chavhan (Mumbai, India), J. Leuppi (Liestal, Switzerland), A. Leuppi-Taegetmeyer (Liestal, Switzerland), P. Chhajed (Mumbai, India)
| |
Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan
S. Hisata (Tochigi, Japan), M. Bando (Tochigi, Japan), S. Homma (Tokyo, Japan), K. Kataoka (Aichi, Japan), T. Ogura (Kanagawa, Japan), S. Izumi (Tokyo, Japan), S. Sakamoto (Tokyo, Japan), Y. Saito (Tokyo, Japan), K. Watanabe (Kyoto, Japan), Y. Shimizu (Tochigi, Japan), M. Kato (Tokyo, Japan), N. Inase (Tokyo, Japan)
| |
Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: Real world experiencefrom a tertiary university hospital
S. Kim (Seoul, Republic of Korea), J. Shin (Seoul, Republic of Korea), M. Song (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), Y. Kang (Seoul, Republic of Korea)
| |
Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg).
E. Krauss (Giessen, Germany), S. Tello (Giessen, Germany), R. Dartsch (Giessen, Germany), M. Korfei (Giessen, Germany), P. Mahavadi (Giessen, Germany), M. Stoehr (Giessen, Germany), J. Wilhelm (Giessen, Germany), R. Majeed (Giessen, Germany), P. Bonniaud (Dijon, France), C. Vancheri (Catania, Italy), A. Wells (London, United Kingdom), W. Seeger (Giessen, Germany), B. Crestani (Paris, France), A. Guenther (Giessen, Germany)
| |
Impact of tidal volume, GAP index and anti-fibrotic treatment on disease progression and mortality in IPF patients
E. Krauss (Giessen, Germany), B. Ait Ilalne (Paris, France), C. Knittel (Giessen, Germany), J. Wilhelm (Giessen, Germany), R. Dartsch (Giessen, Germany), S. Tello (Giessen, Germany), P. Mahavadi (Giessen, Germany), M. Korfei (Giessen, Germany), W. Seeger (Giessen, Germany), B. Crestani (Paris, France), A. Guenther (Giessen, Germany)
| |
Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
Y. Qiu (Princeton, NJ, United States of America), R. Zhao (Princeton, NJ, United States of America), B. Elpers (Princeton, NJ, United States of America), Y. Wang (Ann Arbor, MI, United States of America), L. Xie (Ann Arbor, MI, United States of America), J. Tang (Ann Arbor, MI, United States of America), A. Fischer (Princeton, NJ, United States of America)
| |
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
A. Stanziola (Napoli (NA), Italy), D. Pentangelo (Napoli (NA), Italy), R. D'Angelo (Napoli (NA), Italy), L. Capitelli (Napoli (NA), Italy), R. Rega (Napoli (NA), Italy), M. Bocchino (Napoli (NA), Italy), U. Malapelle (Napoli (NA), Italy)
| |
Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation
V. Cottin (Lyon, France), S. Guéguen (Paris, France), S. Jouneau (Rennes, France), H. Nunes (Avicenne, France), B. Crestani (Paris, France), P. Bonniaud (Dijon, France), L. Wemeau (Lilles, France), D. Israel-Biet (Paris, France), M. Chevereau (Paris, France), I. Dufaure-Garé (Paris, France), S. Amselem (Paris, France), A. Clément (Paris, France)
| |
Association between antifibrotic medications and pneumothorax or pneumomediastinum in patients with idiopathic pulmonary fibrosis
T. Akamatsu (Shizuoka, Japan), H. Nakayasu (Shizuoka, Japan), K. Tamura (Shizuoka, Japan), T. Masuda (Shizuoka, Japan), S. Takahashi (Shizuoka, Japan), Y. Tanaka (Shizuoka, Japan), H. Watanabe (Shizuoka, Japan), Y. Kishimoto (Shizuoka, Japan), K. Oishi (Shizuoka, Japan), M. Saigusa (Shizuoka, Japan), A. Yamamoto (Shizuoka, Japan), S. Morita (Shizuoka, Japan), K. Asada (Shizuoka, Japan), T. Shirai (Shizuoka, Japan)
| |
Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study
V. Poletti (Forlì, Italy), C. Albera (Turin, Italy), S. Harari (Milan, Italy), A. Pesci (Monza, Italy), A. Ori (Modena, Italy), G. Crespi (Milan, Italy), B. Campolo (Milan, Italy), C. Vancheri (Catania, Italy)
| |
Results of antifibrotic drugs in the treatment of idiopathic pulmonary fibrosis. A real life study.
J. Hernandez Borge (Badajoz, Spain), A. Castañar Jover (Badajoz, Spain), L. Sierra Murillo (Badajoz, Spain), P. Iñigo Naranjo (Badajoz, Spain), S. Hernández Gómez (Badajoz, Spain), A. Sanz Cabrera (Badajoz, Spain)
| |
GAP scoring system in IPF patients treated with antifibrotics: prognostic performance and 1- to 3- years mortality: a retrospective study
L. De Sadeleer (Leuven, Belgium), T. Goos (Leuven, Belgium), J. Yserbyt (Leuven, Belgium), S. Verleden (Leuven, Belgium), W. Wuyts (Leuven, Belgium)
| |
Characterize Idiopathic Pulmonary Fibrosis using Respiratory Oscillometry
J. Wu (Toronto, Canada), A. Vasileva (Toronto, Canada), E. Chang (Toronto, Canada), J. Ma (Toronto, Canada), Q. Huang (Toronto, Canada), A. Cassano (Toronto, Canada), M. Binnie (Toronto, Canada), S. Shapera (Toronto, Canada), J. Fisher (Toronto, Canada), C. Ryan (Toronto, Canada), C. Chow (Toronto, Canada)
| |